Information for consumers
GILENYA is used to treat adults with the relapsing and remitting form of multiple sclerosis (MS). MS is an unpredictable, often disabling disease of the central nervous system. GILENYA is generally recommended for MS patients who have not responded well to, or cannot tolerate, one or more of the other therapies for MS.
GILENYA is also used to treat children and adolescent patients between 10 and 18 years of age with the relapsing form of MS.
Animal and post-marketing studies have shown that GILENYA can harm an unborn baby if used during pregnancy.
Before starting treatment with GILENYA, women (including female adolescents and their parent/guardian/caregiver) who could become pregnant or are planning to become pregnant should:
-
talk with their doctor about the risk to an unborn baby;
-
do a pregnancy test to ensure that they are not pregnant, and repeat the pregnancy test at appropriate intervals during treatment;
-
use effective contraception while taking GILENYA and for 2 months after they stop taking it; and
-
discontinue GILENYA 2 months before planning a pregnancy.
Women who become pregnant while taking GILENYA should inform their doctor immediately.
Patients should discuss any questions or concerns about this information with their healthcare professional.
Information for healthcare professionals
Healthcare professionals are advised to discuss the following with all female patients of reproductive potential (including female adolescents and their parent/guardian/caregiver) patients treated with, or to be treated with, GILENYA:
-
the risk of harmful effects associated with GILENYA to a fetus during pregnancy;
-
the need for a negative pregnancy test before starting treatment with GILENYA, which is then repeated at appropriate intervals during treatment;
-
the necessity to use effective contraception during therapy with GILENYA, and for 2 months after stopping GILENYA treatment,
-
the need to discontinue GILENYA 2 months before planning a pregnancy.
If a female patient becomes pregnant while taking GILENYA, stop treatment. Alternative therapy for MS should be considered in women stopping GILENYA treatment due to pregnancy or for planning a pregnancy to avoid the possible return of the disease activity.
Action taken by Health Canada
Health Canada, in collaboration with Novartis Pharmaceuticals Canada Inc., updated the CPM for GILENYA. Health Canada will work with manufacturers of generic versions of fingolimod to update their respective CPMs.
Health Canada is communicating this important safety information to healthcare professionals and Canadians via the
Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication update will be further distributed through the MedEffect™ e-Notice email notification system, as well as through social media channels, including LinkedIn and Twitter.